Journal
EXPERT REVIEW OF ANTI-INFECTIVE THERAPY
Volume 14, Issue 1, Pages 125-135Publisher
TAYLOR & FRANCIS LTD
DOI: 10.1586/14787210.2016.1106938
Keywords
Artemisinin resistance; kelch13; phosphatidylinositol 3-kinase; Plasmodium; ubiquitin; proteasome system; unfolded protein response pathway
Funding
- Cooperative Research Grant of NEKKEN
- Foundation of Strategic Research Projects in Private Universities from the Ministry of Education, Culture, Sports, Science, and Technology of Japan [S0991013]
- Research on Development of New Medical Devices from Japan Agency for Medical Research and development, AMED
- [26305015]
- [26117706]
- [15K08453]
- [26460515]
- Grants-in-Aid for Scientific Research [15K08453, 24590501] Funding Source: KAKEN
Ask authors/readers for more resources
Although artemisinin combination therapies have been deployed as a first-line treatment for uncomplicated malaria in almost all endemic countries, artemisinin-resistant parasites have emerged and have gradually spread across the Greater Mekong subregions. There is growing concern that the resistant parasites may migrate to or emerge indigenously in sub-Saharan Africa, which might provoke a global increase in malaria-associated morbidity and mortality. Therefore, development of molecular markers that enable identification of artemisinin resistance with high sensitivity is urgently required to combat this issue. In 2014, a potential artemisinin-resistance responsible gene, Plasmodium falciparum kelch13, was discovered. Here, we review the genetic features of P. falciparum kelch13 and discuss its related resistant mechanisms and potential as a molecular marker.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available